Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update

Revelation Biosciences, Inc. (NASDAQ:REVB) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 61,700 shares, a decrease of 31.1% from the February 13th total of 89,500 shares. Approximately 6.8% of the company’s shares are sold short. Based on an average trading volume of 214,800 shares, the days-to-cover ratio is presently 0.3 days.

Revelation Biosciences Price Performance

Shares of Revelation Biosciences stock opened at $3.40 on Friday. The stock has a market capitalization of $911,200.00, a price-to-earnings ratio of -0.01 and a beta of 0.17. Revelation Biosciences has a 12 month low of $3.19 and a 12 month high of $60.80. The business has a 50-day moving average of $4.94 and a 200 day moving average of $9.46.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.